cancerBiology180x110

Activin (TGF-β) Receptor ActRIIA Antagonists for Myelodysplastic Syndrome & β-Thalassemia

Two experimental drugs, luspatercept and sotatercept, have shown to be active in myelodysplastic syndrome (MDS), a type of cancer in which the bone marrow does not make enough healthy blood cells and there are abnormal (blast) cells in the blood and/or bone marrow. Continue reading

cancerBiology180x110

New Epidermal Growth Factor Strategies in the Clinic for Glioblastoma & Lung Cancer

Two companies, Celldex and Clovis, reported positive developments with their strategies to target the mutated Epidermal Growth Factor Receptor for patients with glioblastoma and lung cancer. Continue reading

cancerBiology180x110

Tissue Phenomics for Biomarker Identification in Active Immuno-Oncology Therapy

To date, the search for biomarkers to best guide active immunologic therapy selection and monitoring of response has not been fruitful. Unlike molecular targeted therapies and monoclonal antibodies for which the presence of mutated or over-expressed proteins (e.g., Philadelphia Chromosome, B-raf, HER-2, and CD20) is a prerequisite to use, Continue reading

seal

Amgen’s Trebananib Does Not Meet Overall Survival Endpoint in Phase Study of Ovarian Cancer Patients

Angiopoietin inhibitor, trebananib, did not extend overall survival (OS) in a Phase 3 study in ovarian cancer. In the TRINOVA-1 trial of 900 women with recurrent ovarian cancer following platinum-based chemotherapy, patients receiving trebananib plus paclitaxel had a 19.3 month overall survival versus 18.3 months OS for women receiving paclitaxel, alone.  The difference was not statistically significant. Continue reading

cancerBiology180x110

Reprogramming Lung Cancer to Self-Destruct Using TRAIL and CDK9 Inhibitor

CANCER RESEARCH UK scientists have found a drug combination that can trigger the self-destruct process in lung cancer cells – paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool next week. This process is known as apoptosis. Continue reading

cancerBiology180x110

Super Enhancer Switches for Gene Regulation – Syros

Biotech company Syros Pharmaceuticals just raised $53.1 MM in a Series B financing after raising a $30 MM Series A financing in 2013. This is big money for a small company – and, the money comes from some very savvy biotech investment funds. Continue reading

cancerBiology180x110

Unum’s Antibody-Directed T Cells: Differentiated from CAR T-Cell and T Cell Receptor Reprogramming

Unum Therapeutics is a new immunotherapy biotechnology company in which Fidelity Biosciences, Atlas Ventures and Sanofi invested $12 MM in a Series A (first venture round) of investment. Continue reading

cancerBiology180x110

Lentiviral Vectors for Gene Transfection in CAR T-cell Therapy

Novartis entered into a $90 MM deal with Oxford Biomedica for use of its lentiviral vectors with its CAR (chimeric antigen receptor) modified T-cell product, CTL019, being developed with researchers at UPENN. Continue reading